Riyan Alifbi Putera Irsal

Mr. Riyan Alifbi Putera Irsal

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
FMFachrur Rizal Mahendra
Fachrur Rizal Mahendra
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
MDMaheswari Alfira Dwicesaria
Maheswari Alfira Dwicesaria
MAMokhamat Ariefin
Mokhamat Ariefin
JSJosephine Elizabeth Siregar
Josephine Elizabeth Siregar

19 September 2024 in Journal of Taibah University Medical Sciences
Verified
Journal Article
Open access
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
MDMaheswari A. Dwicesaria
Maheswari A. Dwicesaria
TMTiyara F. Mansyah
Tiyara F. Mansyah
FCFernanda Chairunisa
Fernanda Chairunisa
Alzheimer's disease (AD) is posing an increasing global threat and currently lacks effective treatments. Therefore, this study was aimed at exploring phytochemicals in Scabiosa columbaria (S. columbaria) as inhibitors of acetylcholinesterase (AChE), β-site APP cleavage enzyme 1 (BACE1), and TNF-α converting enzyme (TACE) in AD. S. columbaria contains various bioactive compounds, such as chlorogenic acid, linalool, and catechins, which are known for their detoxification properties, capacity to resist and manage harmful moisture buildup, and therapeutic roles in COVID-19. Several studies have also shown that S. columbaria extract has strong antioxidant activity, and may potentially decrease neuroinflammation in AD. Therefore, this study investigated the interactions between S. columbaria phytochemicals and key enzymes associated with AD, thus providing opportunities for the development of new therapeutic candidates. A total of 27 phytochemicals were evaluated for their inhibitory activity against AChE, BACE1, and TACE with YASARA Structure. ADMET profiles and toxicity were assessed. The top candidate compounds underwent 100 ns MD simulations. All ligands met Lipinski's rule and showed low toxicity. Catechins, compared with the known drug galantamine, showed higher inhibitory activity and interacted with additional active sites on AChE, thus suggesting potentially higher efficacy. Moreover, chlorogenic acid showed stronger inhibitory activity against TACE than the control drug (aryl-sulfonamide), thereby suggesting a different mechanism of action. MD simulation revealed that the formed complexes had good stability. However, further exploration is necessary. S. columbaria derivative compounds are promising drug candidates because of their properties, including the affinity of chlorogenic acid toward TACE and hydrogen bond enhancing ligand–receptor interactions. MD simulation indicated stable ligand–protein complexes, and the radius of gyration and MM-PBSA calculations revealed favorable binding and interaction energies. Our findings demonstrate the identified compounds' potential for further drug development.

30 May 2024 in Borneo Journal of Pharmacy
Verified
Journal Article
Open access
PDF file
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
GGGusnia Meilin Gholam
Gusnia Meilin Gholam
DFDzikri Anfasa Firdaus
Dzikri Anfasa Firdaus
NLNovian Liwanda
Novian Liwanda
FCFernanda Chairunisa
Fernanda Chairunisa
Parkinson's disease is a global health challenge affecting over 10 million individuals worldwide, leading to increased disability-adjusted life years (DALYs) and a rise in mortality rates. This study explores the potential anti-Parkinson's properties of Xylocarpus granatum, focusing on its interaction with key enzymes associated with the disease: catechol-O-methyltransferase (COMT), adenosine A2A receptor (A2AR), and monoamine oxidase-B (MAO-B). Using molecular docking and molecular dynamics approaches with YASARA Structure, the ethanol extract of X. granatum was investigated for its mechanism of action. Among 30 compounds, five demonstrated promising binding affinities. Structural flexibility analysis revealed minimal fluctuations in active-site residues, highlighting the stability of key complexes involving kaempferol, epicatechin, epigallocatechin, and native ligands. Molecular Mechanics Poisson–Boltzmann Surface Area (MM-PBSA) simulations provided insights into the binding energy of these complexes. Notably, kaempferol exhibited higher binding energy than the natural ligand, suggesting superior binding affinity. Analysis of the average radius of gyration (Rg) showcased control drug-MAO-B exhibited higher Rg values, indicating a more flexible protein conformation. Confirming mode stability with root mean square deviation (RMSD) analysis shows overall stability, except in the A2AR-bound complex. The study's collective findings underscore the structural stabilization of ligand-protein complexes, contributing valuable insights into the potential anti-Parkinson's properties of X. granatum. These discoveries hold promise for developing more effective therapies for Parkinson's disease and significantly contribute to the neurology field.

12 April 2024 in Proceedings
Verified
Conference Paper
Open access
PDF file
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
MDMaheswari Alfira Dwicesaria
Maheswari Alfira Dwicesaria
MHMuhammad Marsha Azzami Hasibuan
Muhammad Marsha Azzami Hasibuan
Malaria is one of the infectious illnesses causing a public health burden worldwide. Plasmodium vivax (P. vivax) is the most prevalent malaria parasite in Asia and Asia Pacific. P. vivax is resistant to sulfadoxine–pyrimethamine (SP) and mefloquine. This resistance makes it extremely difficult to control and eradicate due to its ability to survive in the liver and reactivate if the person infected has a weakened immune system. Thus, this study aims to inhibit P. vivax via targeting Duffy-binding protein (DBP) with active compounds from Hops (Humulus lupulus). The inhibition of DBP is essential to reduce malaria invasion of human red blood cells. We performed a quality assessment and prediction of the active site of DBP to determine the effectiveness and prediction of ligands in inhibiting DBP. Furthermore, the mechanism and structural stability of active compounds against DBP were evaluated using a combination of molecular docking and molecular dynamics simulation and a density-functional theory (DFT) study. The results showed that rutin had the highest binding of 8.852 kcal/mol. However, after the molecular dynamics simulation was run for 50 ns, the ligand 6-prenylnaringenin via MM-PBSA calculation showed the most positive value of 106.760 kJ/mol. In addition, 6-prenylnaringenin is the most stable ligand via the analysis of root-mean-square deviation backbone (RMSDBb), root-mean-square deviation c-alpha (RMSDCa), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA), radius of gyration (Rg), and the hydrogen bond formation. We conclude that 6-prenylnaringenin has a tight and stable bond with the targeted DBP protein. Finally, we propose the use of 6-prenylnaringenin as a potential antimalarial compound via in silico studies.

12 December 2024 in Journal of Taibah University Medical Sciences
Verified
Journal Article
Open access
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
MDMaheswari Alfira Dwicesaria
Maheswari Alfira Dwicesaria
TMTiyara F. Mansyah
Tiyara F. Mansyah
FCFernanda Chairunisa
Fernanda Chairunisa
Objectives: Dementia, a growing concern globally, affects more than 55 million peopleda number projected to rise to 152 million by 2050. Current medications target Alzheimer's disease, the most prevalent form of dementia. This study investigated Juniperus phoenicea L., a plant used in traditional Chinese medicine, as a potential inhibitor of palmitoyl-protein thioesterase 1 (PPT1), an enzyme associated with dementia. Methods: J. phoenicea phytochemicals were subjected to in silico docking against PPT1 (PDB ID: 1EH5). Docking simulations were performed in YASARA Structure with VINA scoring. Top-ranked ligands were subjected to ADMET analysis (admetlab 2.0, Protox 3.0) and PASS bioactivity prediction. Stability and reactivity were analyzed with DFT calculations (Gaussian 09), and 500 ns MD simulations (YASARA Structure, AMBER 14 force field) to assess protein-ligand complex stability. MM-PBSA was used to calculate binding free energies. Results: The docking simulations identified amentoflavone (-9.6 kcal/mol) as the top hit, followed by ferruginol and quercetin 3-O-pentoside. Amentoflavone formed the most interactions (19) with PPT1. In silico toxicity analysis predicted amentoflavone and quercetin 3-O-pentoside to be safe, whereas ferruginol violated the Pfizer rule. The PASS server indicated a higher probability of activity for quercetin 3-O-pentoside (0.423) than amentoflavone (0.287) for dementia treatment. DFT calculations revealed similar electronic properties for both ligands, although amentoflavone showed slightly more favorable values. MD simulations demonstrated that amentoflavone, compared with to galantamine, had superior binding stability in the PPT1 binding pocket. Conclusion: This in silico study was aimed at identifying potential inhibitors of PPT1 from J. phoenicea phytochemicals, given that PPT1 is a target for developing new dementia medications. Our findings identified amentoflavone as a promising candidate for further investigation. These findings warrant further research to validate this compound's potential as a PPT1 inhibitor for dementia treatment.

15 February 2026 in Biointerface Research in Applied Chemistry
Verified
Journal Article
Open access
FCFernanda Chairunisa
Fernanda Chairunisa
TMTiyara Fany Mansyah
Tiyara Fany Mansyah
DFDzikri Anfasa Firdaus
Dzikri Anfasa Firdaus
MDMaheswari Alfira Dwicesaria
Maheswari Alfira Dwicesaria
Gusnia Meilin GholamGusnia Meilin Gholam
Gusnia Meilin Gholam
RIRiyan Alifbi Putera Irsal
Riyan Alifbi Putera Irsal
Estrogen receptor alpha (ERα) and NUDT5 overexpression are hallmarks of aggressive breast cancer, associated with poor prognosis and therapeutic resistance. This study investigates Eugenia calycina, a plant rich in bioactive compounds, for its potential as an anti-breast cancer agent. We focus on its effects on ERα and NUDT5, an enzyme involved in cancer progression. This study combines molecular docking, DFT, and MD simulations to evaluate Eugenia calycina’s phytochemicals for targeting ERα and NUDT5. The results indicate that PDB2 exhibits superior binding stability compared to reference compounds, as evidenced by lower RMSDbackbone and RMSF values in molecular dynamics simulations. Furthermore, MM-PBSA calculations revealed significantly more negative binding free energies for PDB2 with both NUDT5 and ERα, suggesting stronger interactions. Quantum chemical calculations provided insights into the electronic properties of the compounds, revealing PDB2's potential for favourable interactions due to its smaller HOMO-LUMO energy gap. DFT analysis assessed stability, showing comparable values for the investigated compounds. Molecular docking reveals promising binding affinities of phytochemicals, particularly procyanidin dimer B2. Computational analysis and MD simulation revealed superior stability to reference compounds. While initial predictions indicate a favourable safety profile, further experimental validation is crucial to confirm these findings and their therapeutic potential.